DOBUTAMINE Solution for Injection

Dobutamine

12.5

AMERSHAM HEALTH

Pack size	1 Vial (20 ml)
Dispensing mode
Source
Agent
Retail Price	31.55 AED

Indications

DOBUTAMINE Solution for Injection is used for: Heart failure, Cardiac stress test

Adult Dose

Cardiac Decompensation 0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min Adjust according to patient's BP, heart rate, cardiac and urine output.

Child Dose

Cardiac Decompensation 0.5-1 mcg/kg/min IV continuous infusion initially, then 2-20 mcg/kg/min; not to exceed 40 mcg/kg/min

Renal Dose

Administration

IV Preparation Solution: Dilute 250 mg in 250 mL of compatible solution to yield final concentration of 1000 mcg/mL; not to exceed 5000 mcg/mL The rate of administration and the duration of therapy should be adjusted according to the patient's response, The indicators are: haemodynamic parameters such as heart rate and rhythm, arterial pressure, and, whenever possible, cardiac output and measurements of ventricular filling pressures and signs of pulmonary congestion. Because of its short half-life, Dobutamine Hydrochloride must be administered as a continuous intravenous infusion. Following the initiation of a constant rate infusion, or upon changing the rate, a steady-state dobutamine plasma concentration is achieved within approximately 10 minutes. Thus, loading doses or bolus injections are not necessary and are not recommended.

Contra Indications

Hypersensitivity; idiopathic hypertrophic subaortic stenosis (IHSS).

Precautions

Correct hypovolaemia prior to treatment. Increased risk of rapid ventricular response in patients with atrial fibrillation. Insufficient data to determine the safety and efficacy of dobutamine use after acute MI. Elderly. Neonates. Pregnancy. Lactation: Unknown whether drug is excreted into breast milk; avoid use

Pregnancy-Lactation

Pregnancy category: B Lactation: Unknown whether drug is excreted into breast milk; avoid use

Interactions

Increased cardiac output when used with nitroprusside. Increased vasopressor effect of dobutamine when used with bretylium, guanethidine, oxytocic drugs or TCAs.

Adverse Effects

Side effects of Dobutamine : 1-10% Tachyarrhythmia (10%), Hypertension (7.5%), Eosinophilic myocarditis (<7%), Premature ventricular beats (5%; dose related), Angina (1-3%), Dyspnea (1-3%), Fever (1-3%), Headache (1-3%), Nausea (1-3%), Palpation (1-3%) Frequency Not Defined Cardiac dysrhythmia, Exacerbation of coronary arteriosclerosis, Hypokalemia, Injection-site reactions, Syncope, 10- to 20-mm Hg increase in systolic blood pressure and increase in heart rate of 5 to 15 beats/min Potentially Fatal: Cardiac arrhythmias, allergy (rare), MI and hypotension.

Mechanism of Action

Dobutamine increases contractility and heart rate by stimulating ?-adrenergic receptors in the cardiac tissues.

Note

DOBUTAMINE 12.5 Solution for Injection manufactured by AMERSHAM HEALTH. Its generic name is Dobutamine. DOBUTAMINE is availble in Saudi Arabia. Farmaco SA drug index information on DOBUTAMINE Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Dobutamine :

Concentrate for Peritoneal Dialysis Solution

DOBUJECT ^{50 mg/ml}

CADILA PHARMACEUTICALS LIMITED.

Solution for Infusion

DOBUTAMINE ^{12.5 mg/ml}

ACINO MEA FZ-LLC MIDDLE EAST AFRICA SCIENTFIC OFFICE

Solution for Infusion

DOBUTAMINE ^{12.5 mg/ml}

ACINO MEA FZ-LLC MIDDLE EAST AFRICA SCIENTFIC OFFICE

Concentrate for Solution for Infusion

Cardutrex ^{12.5 mg/ml}

TABUK PHARMACEUTICAL MANUFACTURING CO